Quantitative and qualitative characterization of plasma DNA identifies primary and recurrent colorectal cancer

被引:117
作者
Frattini, M. [1 ]
Gallino, G. [2 ]
Signoroni, S. [1 ]
Balestra, D. [1 ]
Lusa, L. [3 ,4 ]
Battaglia, L. [2 ]
Sozzi, G.
Bertario, L. [5 ]
Leo, E. [2 ]
Pilotti, S. [1 ]
Pierotti, M. A.
机构
[1] Ist Nazl Tumori, Fdn IRCCS, Dept Pathol, I-20133 Milan, Italy
[2] Ist Nazl Tumori, Fdn IRCCS, Colorectal Surg Unit, I-20133 Milan, Italy
[3] Ist Nazl Tumori, Fdn IRCCS, Dept Expt Oncol, I-20133 Milan, Italy
[4] FIRC Inst Mol Oncol IFOM, Milan, Italy
[5] Ist Nazl Tumori, Fdn IRCCS, Prevent Predict Med Unit, I-20133 Milan, Italy
关键词
plasma; quantitative analysis; colorectal cancer; K-Ras; p16(INK4a);
D O I
10.1016/j.canlet.2008.03.021
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Because plasma DNA may be a useful tool for cancer detection, we screened primary tumors and related multiple plasma samples at the time of surgery and during the follow-up period for plasma DNA level as well as for K-Ras mutations and p16(INK4a) promoter hypermethylation in colorectal cancer patients. At the time of surgery, DNA levels were higher in tumor patients than in healthy donors, and K-Ras and p16(INK4a) alterations were detected in 7 and I I cancers respectively, and in all related plasma samples. During the follow-up, plasma DNA levels decrease progressively but rapidly increased when a relapse occurred, whereas K-Ras and p16(INK4a) alterations were detected only in relapsed patients. Therefore, combined quantitative and qualitative analyses of plasma DNA confirm the presence of colorectal cancer, define disease-free status and indicate the presence of relapse. (C) 2008 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:170 / 181
页数:12
相关论文
共 30 条
[1]  
AMADO RG, 2008, J CLIN ONCOL 0303
[2]  
Bearzatto A, 2002, CLIN CANCER RES, V8, P3782
[3]  
Benson AB, 2007, J MANAGE CARE PHARM, V13, pS5
[4]   Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies [J].
Benvenuti, Silvia ;
Sartore-Bianchi, Andrea ;
Di Nicolantonio, Federica ;
Zanon, Carlo ;
Moroni, Mauro ;
Veronese, Silvio ;
Siena, Salvatore ;
Bardelli, Alberto .
CANCER RESEARCH, 2007, 67 (06) :2643-2648
[5]   Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parameters [J].
Bertucci, F ;
Salas, S ;
Eysteries, S ;
Nasser, V ;
Finetti, P ;
Ginestier, C ;
Charafe-Jauffret, E ;
Loriod, B ;
Bachelart, L ;
Montfort, J ;
Victorero, G ;
Viret, F ;
Ollendorff, V ;
Fert, V ;
Giovaninni, M ;
Delpero, JR ;
Nguyen, C ;
Viens, P ;
Monges, G ;
Birnbaum, D ;
Houlgatte, R .
ONCOGENE, 2004, 23 (07) :1377-1391
[6]   Differential gene expression in colon cancer of the caecum versus the sigmoid and rectosigmoid [J].
Birkenkamp-Demtroder, K ;
Olesen, SH ;
Sorensen, FB ;
Laurberg, S ;
Laiho, P ;
Aaltonen, LA ;
Orntoft, TF .
GUT, 2005, 54 (03) :374-384
[7]   Early detection of lung cancer using serum RNA or DNA markers: Ready for "prime time" or for validation? [J].
Bunn, PA .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (21) :3891-3893
[8]   Diagnostic accuracy of faecal occult blood tests used in screening for colorectal cancer: a systematic review [J].
Burch, J. A. ;
Soares-Weiser, K. ;
St John, D. J. B. ;
Duffy, S. ;
Smith, S. ;
Kleijnen, J. ;
Westwood, M. .
JOURNAL OF MEDICAL SCREENING, 2007, 14 (03) :132-137
[9]  
Day DW, 2003, MORSON DAWSONS GASTR, P551
[10]  
DEROOCK W, 2007, ANN ONCOL